Lupin gets USFDA nod to market generic skin treatment medication
New Jersey-based Novel Laboratories Inc has received the approval from the US Food and Drug Administration (USFDA) for Fluocinolone Acetonide Topical Oil, Lupin said in a statement.
)
Lupin on Wednesday said its American subsidiary has received approval from the US health regulator to market a generic product used for treatment of skin issues.
New Jersey-based Novel Laboratories Inc has received approval from the US Food and Drug Administration (USFDA) for Fluocinolone Acetonide Topical Oil, Lupin said in a statement.
The product is the generic version of Hill Dermaceuticals Inc's Derma
New Jersey-based Novel Laboratories Inc has received approval from the US Food and Drug Administration (USFDA) for Fluocinolone Acetonide Topical Oil, Lupin said in a statement.
The product is the generic version of Hill Dermaceuticals Inc's Derm-Smoothe/FS Topical Oil.
Lupin said the product will be manufactured at its Somerset facility in the US.
As per the IQVIA MAT March 2023 data, Fluocinolone Acetonide Topical Oil had estimated annual sales of USD 9 million in the US.
Lupin shares were trading 0.67 percent down at Rs 981.65 apiece on the BSE.
Get Latest Business News, Stock Market Updates and Videos; Check your tax outgo through Income Tax Calculator and save money through our Personal Finance coverage. Check Business Breaking News Live on Zee Business Twitter and Facebook. Subscribe on YouTube.
RECOMMENDED STORIES
12:46 PM IST
Lupin gets 6 observations from USFDA for Pithampur plant
Lupin signs patent licence pact with Takeda for novel gastrointestinal drug in Indian market
Sunsure Energy to supply 21 MW solar power to Lupin
Global brokerages bullish on Lupin a day after its con call; check out target